DEPO Depomed Inc.

5.90
-0.02  -0%
Previous Close 5.92
Open 5.91
Price To book 1.76
Market Cap 371635017
Shares 62,988,986
Volume 810,624
Short Ratio 4.14
Av. Daily Volume 1,775,448

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved January 28, 2011.
GRALISE
Postherpetic neuralgia - shingles
CRL issued May 31, 2013.
SEFELSA
Hot flashes

Latest News

  1. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Depomed, Inc. of Class Action Lawsuit and Upcoming Deadline - DEPO
  2. ETFs with exposure to Depomed, Inc. : September 22, 2017
  3. See what the IHS Markit Score report has to say about Depomed Inc.
  4. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
  5. Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 17th Lead Plaintiff Deadline in Securities Class Action Against Depomed, Inc. (DEPO)
  6. Depomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
  7. DEPOMED INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Depomed, Inc. To Contact The Firm
  8. SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
  9. The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Depomed, Inc. Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (DEPO)
  10. INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
  11. INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Depomed, Inc. (Nasdaq: DEPO) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
  12. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Depomed, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 17, 2017 - DEPO
  13. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
  14. DEPO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Depomed, Inc. and a Lead Plaintiff Deadline of October 17, 2017
  15. SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm
  16. IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Depomed, Inc. and Reminds Investors with Losses to Contact the Firm

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 171040972
  2. 8-K - Current report 171038934
  3. 8-K - Current report 171011557
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011552
  5. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17970105
  6. DEF 14A - Other definitive proxy statements 17965814
  7. 8-K - Current report 17962697
  8. 8-K - Current report 17962655
  9. 8-K - Current report 17955517
  10. 8-K - Current report 17861520